期刊文献+

紫杉醇脂质体联合顺铂、氟尿嘧啶一线治疗晚期胃癌的临床观察 被引量:7

A phase Ⅱ trial of paclitaxel liposome plus cisplatin and 5-fluorouracil as first-line chemotherapy for advanced gastric cancer
暂未订购
导出
摘要 目的:评价紫杉醇脂质体联合顺铂、氟尿嘧啶(PCF方案)一线治疗晚期胃癌的临床疗效和毒副反应。方法:PCF方案一线治疗42例晚期胃癌的具体用法:紫杉醇脂质体175mg/m2,第1天静滴90min;顺铂75mg/m2,第1天静滴;亚叶酸钙400mg/m2,第1天滴注2h;氟尿嘧啶2.6g/m2,亚叶酸钙滴注结束后立即持续泵入46h。21天为1周期,每2周期按RE-SIST标准评价疗效,所有患者至少接受2周期化疗。结果:42例患者共接受192个周期的化疗,所有患者均可评价疗效。完全缓解3例(7.1%),部分缓解20例(47.6%),稳定12例(28.6%),进展7例,总有效率为54.8%,中位进展时间(TTP)6.5个月,中位生存时间(MST)13.9个月。常见的不良反应为血液学毒性,胃肠反应、肌肉酸痛、外周神经毒性较轻,以Ⅰ、Ⅱ级为主。10例(23.8%)发生Ⅲ~Ⅳ级粒细胞减少,伴发热1例(2.4%);Ⅲ级恶心呕吐反应4例(9.5%),Ⅲ级肌肉酸痛3例(7.1%),Ⅲ级外周神经毒性2例(4.7%),无化疗相关性死亡病例。结论:紫杉醇脂质体联合顺铂、氟尿嘧啶(PCF方案)一线治疗晚期胃癌疗效确切,不良反应轻,值得临床推广应用。 Objective:The prognosis of advanced gastric cancer(AGC) is poor,no standard chemotherapy regimens for AGC are available.The study was to evaluate the efficacy and toxicity of paclitaxel liposome plus cisplatin and 5-fluorouracil(PCF regimen) as first-line chemotherapy for AGC patients.Methods:Forty-two patients with pathologically confirmed AGC entered into the study.On day 1,patients were infused with 175 mg/m^2 paclitaxel liposome over 3h,infused with 75mg/m2 cispltin,infused with 400mg/m^2 leucovorin(CF) over 2h,followed by 46h infusion of 5-fluorouracil at 2 600mg/m^2.The cycle was repeated every three weeks.Treatment efficacy was evaluated every two cycles based on the RESIST standard.All patients received at least two cycles of therapy.Results:Patients received a total of 192 cycles of treatment,and all were evaluable for efficacy and toxicity.The overall response rate was 54.8%,3 cases(7.1%) achieved complete responses(CR),20(47.6%)achieved partial responses(PR),12(28.6%)had stable disease(SD),and 7 had progression disease(PD).The median time to progression(TTP) was 6.5 months and the median survival time(MST) was 13.9months.Hematologic toxicity included 10 cases(23.8%) of grade 3-4 neutropenia,one of which was accompanied with fever,the main non-hematologic toxicity included 4 cases of grade of 3 nausea and vomiting(9.5%),3 cases of grade of 3 myalgia(7.1%),and 2 cases of grade of 3 peripheral neuropathy(4.7%),No occurrence of treatment related deaths.Conclusion:PCF regimen is effective and well tolerated as first-line chemotherapy for AGC patients.
出处 《临床肿瘤学杂志》 CAS 2009年第4期332-335,共4页 Chinese Clinical Oncology
关键词 晚期胃癌 化学疗法 紫杉醇脂质体 顺铂 氟尿嘧啶 Advanced gastric cancer Chemotherapy Paclitaxel liposome Cisplatin 5-fluorouacil
  • 相关文献

参考文献14

  • 1Hundahl SA,Phillips JL, Menck HR, et al. The National Cancer Data Base report on poor survival of U. S. gastric carcinoma patients treated with gastrectomy[ J]. Cancer, 2000,88 ( 4 ) :921 - 932.
  • 2Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate ( FEMTX ) plus supportive care with supportiee care alone in patients with non-reseetable gastric cancer [ J]. Br J Cancer, 1995,71 : 587 -591.
  • 3Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil,doxorubicin,and methotrexate in advanced gastric cancer[J]. Cancer, 1993,72:37 -41.
  • 4Glimelius B, Hoffmann K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer [ J ]. Ann Cncol, 1993,5 : 189 - 190.
  • 5Macdonald JS, Philip SS, Woolley PV, et al. 5-Fluorouracil, doxorubicin and mitomycin ( FAM ) combination chemotherapy for advanced gastric cancer[ J]. Ann Inten Med,1980,93:533 -536.
  • 6Wils JA, Klein HO, Wagener DJ, et al. FAMTX ( 5-FU, adriamycin and methotrexate) :A step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer of the Gastrointestinal Tract Cooperative Group[J]. J Clin Oncol, 1991,9:827 - 831.
  • 7Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in adcanced esophagogatric cancer [ J ]. J Clin oncol, 1997,15:261 - 267.
  • 8Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase Ⅲ trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in treatment of cancer. Gastrointestinal Tract Cancer Cooperative Group [ J ]. J Clin Oncol,2000,18 (14) :2648 - 2657.
  • 9Ross P, Nicolson M, Cunninghan D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil ( PVI 5-FU ) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer[J]. J Clin Oncol, 2002,20 : 1996 - 2004.
  • 10Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of doctaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer :A report of the V325 study group [ J ]. J Clin Oncol,2006, 24(31 ) :4991 -4997.

同被引文献65

  • 1陈智伟,廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用[J].中国肿瘤,2004,13(10):616-618. 被引量:185
  • 2Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:347
  • 3时建明,张明,杨晖,王彬.奥沙利铂联合ELF治疗40例晚期胃癌的临床近期疗效及不良反应观察[J].南京医科大学学报(自然科学版),2006,26(11):1080-1081. 被引量:4
  • 4陈凝,杨觅,钱晓萍,禹立霞,刘宝瑞.紫杉醇脂质体腹腔给药对S_(180)腹水瘤小鼠的疗效[J].南京医科大学学报(自然科学版),2007,27(7):706-710. 被引量:4
  • 5Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55:74-108.
  • 6Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000, 50:7-33.
  • 7Sokamoto J, Clink D, Kondo K, et al. Phase II study of a 4- week capecitabine regimen in advanced or recurrent gastric cancer[J]. Aticancer Drug, 2006, 17(2) :231-236.
  • 8Hong YS, Song SY, Lee SI, et al. A phase II trail of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer[J]. Ann Oncol, 2004, 15 (9) : 1344- 1347.
  • 9Kobayashi M, Oba K, Sakamoto J, et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gasric cancer in Japan [ J ]. Gasric Cancer, 2007, 10( 1 ) :52-57.
  • 10Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatin (DC) versus 5-fluoreuracil-leucovorin- eisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase Ⅲ study[J]. J Clin Oncol, 2008, 26(suppl) : abstr 4512.

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部